NGM Biopharmaceuticals outlines 2023 corporate priorities

NGM Biopharmaceuticals is providing an overview of highlights from 2022 and outlining its 2023 corporate priorities. "In 2022, NGM Bio sharpened its focus on oncology solid-tumor clinical development. We reported promising preliminary data from our first myeloid checkpoint inhibitor program, NGM707, and advanced our additional myeloid checkpoint inhibitor programs, NGM438 and NGM831, into the clinic," said David Woodhouse, Ph.D., Chief Executive Officer at NGM Bio. Dr. Woodhouse continued, "Our strategy in 2023 is to focus our clinical development efforts on our portfolio of four clinical-stage oncology programs while operating our prolific drug discovery engine to generate next-generation biologic therapeutics. For our programs outside this area of focus, in retinal disease and NASH, we will seek development partners with relevant domain expertise. We’re committed to developing transformative therapeutics for patients and energized by the opportunities we see in this next chapter of the NGM Bio story." 2023 Strategic Priorities: Oncology: Advance the ongoing Phase 1/2 signal-seeking trial of NGM707 and the ongoing Phase 1 signal-seeking trials of NGM831 and NGM438, all being studied in patients with advanced solid tumors. NASH: Read out topline data from ALPINE 4, the Phase 2b trial of aldafermin in patients with F4 NASH, in Q2 2023. Business Development: Consistent with NGM Bio’s business model since inception, business development will remain a key priority to allow the company to focus development and financial resources on oncology clinical development and new molecule generation. NGM Bio will seek partners for the following programs: Aldafermin; NGM621; NGM936